A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos.
We conducted an open, randomized clinical trial of oral dihydroartemisinin-piperaquine (DP) versus artesunate-mefloquine (AM) in 300 patients in Laos with uncomplicated Plasmodium falciparum malaria as part of a multicentre study in Asia. Survival analysis and adjustment for re-infection showed that...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2010
|
| _version_ | 1826260931998384128 |
|---|---|
| author | Mayxay, M Keomany, S Khanthavong, M Souvannasing, P Stepniewska, K Khomthilath, T Keola, S Pongvongsa, T Phompida, S Ubben, D Valecha, N White, N Newton, P |
| author_facet | Mayxay, M Keomany, S Khanthavong, M Souvannasing, P Stepniewska, K Khomthilath, T Keola, S Pongvongsa, T Phompida, S Ubben, D Valecha, N White, N Newton, P |
| author_sort | Mayxay, M |
| collection | OXFORD |
| description | We conducted an open, randomized clinical trial of oral dihydroartemisinin-piperaquine (DP) versus artesunate-mefloquine (AM) in 300 patients in Laos with uncomplicated Plasmodium falciparum malaria as part of a multicentre study in Asia. Survival analysis and adjustment for re-infection showed that the 63-day cure rates (95% confidence interval [CI]) were 100% for AM and 99.5% (96.4-99.8%) for DP. The 63-day cure rates per protocol were 99% (97 of 98) for AM and 99.5% (196 of 197) for DP (P = 0.55). The difference (AM minus DP) in cure rates (95% CI) was -0.5% (-5.1 to 2.0%), which is within the 5% non-inferiority margin. The median fever and parasite clearance times were also similar for AM and DP. The proportion of patients with at least one recorded potential adverse event was significantly higher in the AM group (38 of 87, 44%) than in the DP group (57 of 182, 31%) (relative risk = 0.6, 95% CI = 0.4-0.9; P = 0.04). Dihydroartemisinin-piperaquine is not inferior to AM in the treatment of uncomplicated P. falciparum malaria in Laos and is associated with fewer adverse effects. The results of this study were similar to those of the larger multicentre study. |
| first_indexed | 2024-03-06T19:13:34Z |
| format | Journal article |
| id | oxford-uuid:1795a8d3-b1d3-48b7-966d-5c74269d0d0f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:13:34Z |
| publishDate | 2010 |
| record_format | dspace |
| spelling | oxford-uuid:1795a8d3-b1d3-48b7-966d-5c74269d0d0f2022-03-26T10:38:16ZA phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:1795a8d3-b1d3-48b7-966d-5c74269d0d0fEnglishSymplectic Elements at Oxford2010Mayxay, MKeomany, SKhanthavong, MSouvannasing, PStepniewska, KKhomthilath, TKeola, SPongvongsa, TPhompida, SUbben, DValecha, NWhite, NNewton, PWe conducted an open, randomized clinical trial of oral dihydroartemisinin-piperaquine (DP) versus artesunate-mefloquine (AM) in 300 patients in Laos with uncomplicated Plasmodium falciparum malaria as part of a multicentre study in Asia. Survival analysis and adjustment for re-infection showed that the 63-day cure rates (95% confidence interval [CI]) were 100% for AM and 99.5% (96.4-99.8%) for DP. The 63-day cure rates per protocol were 99% (97 of 98) for AM and 99.5% (196 of 197) for DP (P = 0.55). The difference (AM minus DP) in cure rates (95% CI) was -0.5% (-5.1 to 2.0%), which is within the 5% non-inferiority margin. The median fever and parasite clearance times were also similar for AM and DP. The proportion of patients with at least one recorded potential adverse event was significantly higher in the AM group (38 of 87, 44%) than in the DP group (57 of 182, 31%) (relative risk = 0.6, 95% CI = 0.4-0.9; P = 0.04). Dihydroartemisinin-piperaquine is not inferior to AM in the treatment of uncomplicated P. falciparum malaria in Laos and is associated with fewer adverse effects. The results of this study were similar to those of the larger multicentre study. |
| spellingShingle | Mayxay, M Keomany, S Khanthavong, M Souvannasing, P Stepniewska, K Khomthilath, T Keola, S Pongvongsa, T Phompida, S Ubben, D Valecha, N White, N Newton, P A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. |
| title | A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. |
| title_full | A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. |
| title_fullStr | A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. |
| title_full_unstemmed | A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. |
| title_short | A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. |
| title_sort | phase iii randomized non inferiority trial to assess the efficacy and safety of dihydroartemisinin piperaquine in comparison with artesunate mefloquine in patients with uncomplicated plasmodium falciparum malaria in southern laos |
| work_keys_str_mv | AT mayxaym aphaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT keomanys aphaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT khanthavongm aphaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT souvannasingp aphaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT stepniewskak aphaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT khomthilatht aphaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT keolas aphaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT pongvongsat aphaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT phompidas aphaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT ubbend aphaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT valechan aphaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT whiten aphaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT newtonp aphaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT mayxaym phaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT keomanys phaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT khanthavongm phaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT souvannasingp phaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT stepniewskak phaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT khomthilatht phaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT keolas phaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT pongvongsat phaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT phompidas phaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT ubbend phaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT valechan phaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT whiten phaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos AT newtonp phaseiiirandomizednoninferioritytrialtoassesstheefficacyandsafetyofdihydroartemisininpiperaquineincomparisonwithartesunatemefloquineinpatientswithuncomplicatedplasmodiumfalciparummalariainsouthernlaos |